Bart van Rhijn
Director of Finance/CFO chez NANOBIOTIX
Fortune : - $ au 31/03/2024
Profil
Bart van Rhijn is currently the Chief Financial Officer at Nanobiotix SA since 2021.
Prior to this, he was the Chief Financial Officer at Servier Pharmaceuticals LLC from 2018 to 2021 and Head-Finance at Galderma International SAS from 2015 to 2018.
He has a graduate degree from the University of Leiden and an MBA from Olin Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NANOBIOTIX SA
-.--% | 24/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Bart van Rhijn
| Sociétés | Poste | Début |
|---|---|---|
| NANOBIOTIX | Director of Finance/CFO | 01/06/2021 |
Anciens postes connus de Bart van Rhijn
| Sociétés | Poste | Fin |
|---|---|---|
Servier Pharmaceuticals LLC
 Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company is based in Boston, MA. Servier Pharmaceuticals continues to build a treatment portfolio with a current focus on oncology within acute lymphoblastic leukemia. The company invests in innovative research and development through development or partnerships to best address the unmet needs of patients. Additionally, the company is proud to offer financial assistance to not only support patients and their families but a variety of focused advocacy groups and healthcare professionals as well. Servier Pharmaceuticals is committed to engaging with patients, caregivers, families, and patient organizations to ensure their voices are heard in every initiative. The company's responsibility is to help make the world a better place for patients and their families, and it strives to have consistent and concise transparency throughout all clinical trials and research and development for the benefit of all patients. The company was founded in 1954. The CEO is David K. Lee. | Director of Finance/CFO | 01/05/2021 |
Galderma International SAS
 Galderma International SAS Pharmaceuticals: MajorHealth Technology Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France. | Corporate Officer/Principal | 01/08/2018 |
Formation de Bart van Rhijn
| University of Leiden | Graduate Degree |
| Olin Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NANOBIOTIX | Health Technology |
| Entreprise privées | 2 |
|---|---|
Galderma International SAS
Galderma International SAS Pharmaceuticals: MajorHealth Technology Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France. | Health Technology |
Servier Pharmaceuticals LLC
Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company is based in Boston, MA. Servier Pharmaceuticals continues to build a treatment portfolio with a current focus on oncology within acute lymphoblastic leukemia. The company invests in innovative research and development through development or partnerships to best address the unmet needs of patients. Additionally, the company is proud to offer financial assistance to not only support patients and their families but a variety of focused advocacy groups and healthcare professionals as well. Servier Pharmaceuticals is committed to engaging with patients, caregivers, families, and patient organizations to ensure their voices are heard in every initiative. The company's responsibility is to help make the world a better place for patients and their families, and it strives to have consistent and concise transparency throughout all clinical trials and research and development for the benefit of all patients. The company was founded in 1954. The CEO is David K. Lee. | Health Technology |
